GENESIS-II study reveals 30-day results for the hydra self-expanding transcatheter aortic valve
Key findings reveal the Hydra THV's outstanding safety and efficacy, with a low cardiovascular mortality rate of 2.5 per cent and…
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.